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Ovarian cancer screening has been described in scientific reports [1–4], as well as in reviews
and summaries. Scientific reports contain the facts of a study, while reviews and summaries present
interpretations. Presented here are scientific reports which add considerable information to the area of
early stage ovarian cancer detection and the application of this detection to ovarian cancer screening.
In the present reports:
Froyman and collaborators have assessed and compared the performance of different
ultrasound-based International Ovarian Tumor Analysis (IOTA) strategies and subjective assessment
for the diagnosis of early stage ovarian malignancy. This important study establishes that the
approaches that are taken present a good discrimination between early stage ovarian malignancy and
benign abnormalities of the ovary [5].
Baldwin and co-investigators have realized that oophorectomy confers protection against ovarian
cancer to the population that has undergone this surgical procedure. As a consequence, risk estimates
of ovarian cancer must be adjusted for this protection so that true risk is not underestimated.
When these adjustments were made, the rates of ovarian cancer were substantially higher when
salpingo-oophorectomy was considered [6].
Ore and associates have examined how frequently and confidently healthy women report
symptoms during surveillance for ovarian cancer. They found that the frequency of symptoms
relevant to ovarian cancer was more than two hundred times higher than the occurrence of ovarian
cancer and that 80.1% of women expressed confidence in the symptoms they reported [7].
Miller and her investigational team compared complications of surgical intervention for
participants in the Kentucky Ovarian Cancer Screening Program to results from the Prostate, Lung,
Colorectal, and Ovarian Cancer Screening trial (PLCO). They report that complications resulting
from surgery performed in the Kentucky Ovarian Cancer Screening Program were infrequent and
significantly fewer than reported in the Prostate, Lung, Colorectal and Ovarian Cancer Screening
trial. Complications observed were mostly minor (93%) and were more common in cancer versus
non-cancer surgery [8].
Ormsby and collaborators present arguments in favor of serial ultrasonography as an alternative
to immediate surgery so that any benign abnormality will have the opportunity to resolve.
Ultimately, this report presents arguments relative to the benefits of surveillance [9].
Ed Pavlik presents ten critical considerations for ovarian cancer screening, some of which have
not been realized in published ovarian screening study reports. These considerations are presented
in depth along with illustrations of how they impact the outcomes of ovarian cancer screening trials.
These considerations highlight effects that have an important bearing on ovarian screening outcomes
and their interpretations [10].
Michael Andrykowski presents considerations that have psychological and behavioral impacts
on individuals participating in ovarian screening. His findings suggest that a “normal” screening test
result can have psychological benefits, including increased positive affect and beliefs in the efficacy of
screening. Moreover, any psychological or behavioral harms attributable to ovarian cancer screening
are generally very modest in severity and duration, and might be counterbalanced by psychological
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benefits accruing to women who participate in routine ovarian cancer screening and receive normal
test results [11].
Koshiyama and collaborators present current issues that are related to ovarian cancer and
screening. They report that the efficacy of ovarian cancer screening may be higher in Asia than
in Europe and the USA. These investigators review the re-analysis of PLCO screening data when
cancers presenting more than one year after screening are excluded and show a significant survival
benefit in the PLCO screening. They highlight their views by considering the difficulties of detecting
Type II ovarian carcinomas [12].
Chris Smith examines the effects that ovarian cancer has on patients and their families. The rigors
of treatment conspire with the inevitability of recurrence in the eyes of this first year resident in
Obstetrics and Gynecology. He postulates that in the absence of effective therapies, early detection
holds the greatest promise [13].
Fred Ueland relates the 50 year history of biomarkers and ultrasound in the context of ovarian
cancer. He emphasizes the serial application of both biomarkers and ultrasound. Importantly, he looks
to what the future may bring with regard to the utilization of biomarkers and ultrasound in routine
patient exams [14].
Taken together, these authors have provided both original data and overviews of ovarian cancer
screening studies that enhance the present interpretation of this type of screening.
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